Biomarker Clinical Phase Outsourcing Market: Growth Opportunities Through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Biomarker Clinical Phase Outsourcing Services Market In 2026 And 2030?
The market size for biomarker clinical phase outsourcing services has expanded significantly in recent years. It is anticipated to increase from $11.91 billion in 2025 to $14.62 billion in 2026, registering a compound annual growth rate (CAGR) of 22.7%. This historical growth can be linked to the increasing complexity of clinical trial designs, a rise in oncology clinical research activity, the expansion of biomarker-driven drug development, the enlargement of translational research programs, and greater collaboration with specialized service providers.
The biomarker clinical phase outsourcing services market is projected to experience substantial expansion in the coming years, anticipated to reach $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. This projected growth during the forecast period is largely driven by factors such as the heightened demand for personalized medicine trials, the increasing integration of AI-driven biomarker analytics, the broadening scope of multi-biomarker clinical studies, expanding investments in precision oncology, and greater regulatory focus on biomarker validation. Key trends anticipated for the forecast period encompass a rise in the outsourcing of biomarker clinical trial activities, increased utilization of predictive and prognostic biomarkers, greater integration of omics-based biomarker analysis, an expansion in companion diagnostics development, and a stronger emphasis on precision medicine trials.
Access Your Free Sample Report For In-Depth Market Analysis:
What Factors Are Contributing To The Growth Of The Biomarker Clinical Phase Outsourcing Services Market?
The increasing number of clinical trials is projected to fuel the expansion of the biomarker clinical phase outsourcing services market in the future. These trials, defined as research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are proliferating due to advancements in medical research, a growing incidence of chronic diseases, increased funding from both public and private sectors, and the rising demand for novel treatments and therapies. Outsourcing providers often possess specialized knowledge and proficiency in biomarker discovery, validation, and analysis, which enhances the quality and dependability of the biomarker data gathered throughout the trial process. For instance, in November 2025, the National Library of Medicine, a US-based biomedical library, reported via ClinicalTrials.gov that it currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Consequently, the growth in clinical trials is expected to drive the expansion of the biomarker clinical phase outsourcing services market.
How Are Different Segments Classified In The Biomarker Clinical Phase Outsourcing Services Market Segment Analysis?
The biomarker clinical phase outsourcing services market covered in this report is segmented –
1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types
2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis
3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies, Biotechnology Companies
Subsegments:
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers
2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers
4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers
5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers
What Trends Are Shaping The Future Of The Biomarker Clinical Phase Outsourcing Services Market?
Leading companies in the biomarker clinical phase outsourcing services are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to secure a competitive advantage in the market. These methods are utilized for biomarker analysis, providing quick and accurate assessment of immune responses and cellular markers. For instance, in May 2024, KCAS Bio, a U.S.-based bioanalytical CRO offering GLP/GCP-compliant biomarker and immune-monitoring services, formed a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this collaboration, KCAS Bio installed harmonized spectral cytometers at Crux Biolabs’ facilities, enabling clients to utilize high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This partnership bolsters KCAS’s biomarker development and immune-monitoring capabilities by delivering rapid, precise evaluation of cellular biomarkers in clinical trials, helping clients generate high-quality data essential for regulatory submissions and accelerating drug development.
Who Are The Companies Driving Activity In The Biomarker Clinical Phase Outsourcing Services Market?
Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.
Get The Full Biomarker Clinical Phase Outsourcing Services Market Report:
Which Region Represents The Largest Share Of The Biomarker Clinical Phase Outsourcing Services Market?
North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biomarker Clinical Phase Outsourcing Services Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company
Biologics Outsourcing Market Report 2026
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report
Biomarker Discovery Outsourcing Services Market Report 2026
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
